Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Session Title: Innovations in Assessment and Treatment of Fibrosing Lung Disease Session ID: ...

I took EcoFlow’s latest portable power station, the Delta 3 Plus, into the wild (literally). I brought it on a five-day ...

Adrenaline delivered with liquid or powder nasal sprays is as effective, and sometimes even better, than injected adrenaline, ...

Amazon has dropped the EF Ecoflow Delta Pro portable power station to $1,400, which is a massive 50% off its regular price.

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

DLco% (a measure of pulmonary gas transfer) was chosen as the primary endpoint in the IMPALA-2 Phase 3 clinical trial because it is a standardized measure of pulmonary gas transfer widely used in ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Zookeepers spent three years teaching 16-year-old Mahiri how to confidently use an inhaler, which Banham Zoo designed to ...

-- Approximately 5,500 Autoimmune PAP Patients in the U.S. Identified in the Updated Analysis that Leveraged a More Recent and Comprehensive Claims Data Source -- -- New England Journal of Medicine ...

We use Eflow 1.5.6. It appears that all layers between the physical TPM and the IoT Edge are functioning correctly yet the command still loops with Retrying to retrieve TPM information... Finally, we ...

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF ...

-- Reached Alignment with the U.S. Food and Drug Administration (FDA) on Information Needed for Resubmission of the Biologics License Application (BLA) for MOLBREEVI* as a Treatment for Autoimmune ...